线粒体分裂
胰岛素抵抗
骨骼肌
内科学
内分泌学
线粒体
DNM1L型
生物
胰岛素受体
MFN2型
胰岛素
氧化磷酸化
细胞生物学
医学
线粒体DNA
线粒体融合
生物化学
基因
作者
Christopher L. Axelrod,Ciarán E. Fealy,Melissa L. Erickson,Gangarao Davuluri,Hisashi Fujioka,Wagner S. Dantas,Emily Huang,Kathryn Pergola,Jacob T. Mey,W. T. King,Anny Mulya,Daniel S. Hsia,Bartolomé Burguera,Bernard Tandler,Charles L. Hoppel,John P. Kirwan
标识
DOI:10.1016/j.metabol.2021.154803
摘要
A diminution in skeletal muscle mitochondrial function due to ectopic lipid accumulation and excess nutrient intake is thought to contribute to insulin resistance and the development of type 2 diabetes. However, the functional integrity of mitochondria in insulin-resistant skeletal muscle remains highly controversial.19 healthy adults (age:28.4 ± 1.7 years; BMI:22.7 ± 0.3 kg/m2) received an overnight intravenous infusion of lipid (20% Intralipid) or saline followed by a hyperinsulinemic-euglycemic clamp to assess insulin sensitivity using a randomized crossover design. Skeletal muscle biopsies were obtained after the overnight lipid infusion to evaluate activation of mitochondrial dynamics proteins, ex-vivo mitochondrial membrane potential, ex-vivo oxidative phosphorylation and electron transfer capacity, and mitochondrial ultrastructure.Overnight lipid infusion increased dynamin related protein 1 (DRP1) phosphorylation at serine 616 and PTEN-induced kinase 1 (PINK1) expression (P = 0.003 and P = 0.008, respectively) in skeletal muscle while reducing mitochondrial membrane potential (P = 0.042). The lipid infusion also increased mitochondrial-associated lipid droplet formation (P = 0.011), the number of dilated cristae, and the presence of autophagic vesicles without altering mitochondrial number or respiratory capacity. Additionally, lipid infusion suppressed peripheral glucose disposal (P = 0.004) and hepatic insulin sensitivity (P = 0.014).These findings indicate that activation of mitochondrial fission and quality control occur early in the onset of insulin resistance in human skeletal muscle. Targeting mitochondrial dynamics and quality control represents a promising new pharmacological approach for treating insulin resistance and type 2 diabetes.NCT02697201, ClinicalTrials.gov.
科研通智能强力驱动
Strongly Powered by AbleSci AI